VJHemOnc is committed to improving our service to you

SOHO 2020 | Harnessing apoptosis in AML

VJHemOnc is committed to improving our service to you

Marina Konopleva

Marina Konopleva, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, outlines clinical updates evaluating the use of agents targeting apoptotic signals in acute myeloid leukemia (AML), including venetoclax, a BCL-2 inhibitor, in combination with azacitidine, as well as triplet combinations with FLT3 inhibitors or novel monoclonal antibodies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter